Literature DB >> 12069013

In vitro susceptibility to quinolones of Francisella tularensis subspecies tularensis.

Anders Johansson1, Sandra K Urich, May C Chu, Anders Sjöstedt, Arne Tärnvik.   

Abstract

Francisella tularensis is a potent pathogen and a possible bioterrorism agent, for which quinolones offer promising new therapeutic options. There are, however, no data on the susceptibility to quinolones of natural isolates of F. tularensis tularensis, the highly virulent North American subspecies. In the present study, 8 isolates of F. tularensis tularensis, originating from 8 different states of the USA, and 16 US isolates of F. tularensis holarctica were tested. All 24 isolates showed MIC values < or = 0.125 mg/l to 6 different quinolones. Against ciprofloxacin, the predominant quinolone used to date in therapy against subspecies holarctica, MIC values were consistently < or = 0.064 mg/l. Thus quinolones seem to be promising options for the treatment of tularemia, including cases caused by the highly virulent subspecies F. tularensis tularensis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12069013     DOI: 10.1080/00365540110080773

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  11 in total

1.  In vitro susceptibility of isolates of Francisella tularensis types A and B from North America.

Authors:  Sandra K Urich; Jeannine M Petersen
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

2.  In Vitro Antibiotic Susceptibilities of Francisella tularensis Determined by Broth Microdilution following CLSI Methods.

Authors:  Henry S Heine; Lynda Miller; Stephanie Halasohoris; Bret K Purcell
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

3.  Resistance of Francisella novicida to fosmidomycin associated with mutations in the glycerol-3-phosphate transporter.

Authors:  Ryan S Mackie; Elizabeth S McKenney; Monique L van Hoek
Journal:  Front Microbiol       Date:  2012-08-09       Impact factor: 5.640

4.  A new dye uptake assay to test the activity of antibiotics against intracellular Francisella tularensis.

Authors:  Vivien Sutera; Yvan Caspar; Sandrine Boisset; Max Maurin
Journal:  Front Cell Infect Microbiol       Date:  2014-03-18       Impact factor: 5.293

Review 5.  Francisella tularensis Susceptibility to Antibiotics: A Comprehensive Review of the Data Obtained In vitro and in Animal Models.

Authors:  Yvan Caspar; Max Maurin
Journal:  Front Cell Infect Microbiol       Date:  2017-04-11       Impact factor: 5.293

6.  Laboratory analysis of tularemia in wild-trapped, commercially traded prairie dogs, Texas, 2002.

Authors:  Jeannine M Petersen; Martin E Schriefer; Leon G Carter; Yan Zhou; Tara Sealy; Darcy Bawiec; Brook Yockey; Sandra Urich; Nordin S Zeidner; Swati Avashia; Jacob L Kool; Jan Buck; Connie Lindley; Leos Celeda; John A Monteneiri; Kenneth L Gage; May C Chu
Journal:  Emerg Infect Dis       Date:  2004-03       Impact factor: 6.883

7.  Bis-indolic compounds as potential new therapeutic alternatives for tularaemia.

Authors:  Yvan Caspar; Vivien Sutera; Sandrine Boisset; Jean-Noël Denis; Max Maurin
Journal:  Front Cell Infect Microbiol       Date:  2014-02-27       Impact factor: 5.293

Review 8.  Comparative review of Francisella tularensis and Francisella novicida.

Authors:  Luke C Kingry; Jeannine M Petersen
Journal:  Front Cell Infect Microbiol       Date:  2014-03-13       Impact factor: 5.293

Review 9.  New therapeutic approaches for treatment of tularaemia: a review.

Authors:  Sandrine Boisset; Yvan Caspar; Vivien Sutera; Max Maurin
Journal:  Front Cell Infect Microbiol       Date:  2014-03-28       Impact factor: 5.293

10.  Long-Lasting Fever and Lymphadenitis: Think about F. tularensis.

Authors:  Maria Vittoria Longo; Katia Jaton; Paola Pilo; David Chabanel; Véronique Erard
Journal:  Case Rep Med       Date:  2015-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.